Literature DB >> 20953810

Dementia and cognitive impairment in amyotrophic lateral sclerosis: a review.

Maria Teresa Giordana1, Patrizia Ferrero, Silvia Grifoni, Alessia Pellerino, Andrea Naldi, Anna Montuschi.   

Abstract

Amyotrophic lateral sclerosis (ALS) is generally considered to be a paradigm of pure motor neuron disorder; nevertheless, the possible occurrence of cognitive impairment up to a frank dementia in patients affected by ALS is recognized. The appraisal of the cognitive impairment in ALS patients is crucial not only to the therapeutic trials of this incurable disease, but also to the planning of care, compliance to interventions, the end-of-life decisions. The cognitive/behavioral changes of ALS patients are consistent with frontotemporal dysfunctions; the overlap of neuropathological features of ALS and frontotemporal lobe degeneration (FTLD) supports, in addition, the putative spectrum of ALS and FTD. In the present review, the pertinent clinical, genetic, neuropathological, neuropsychological and neuroimaging data of the literature are comprehensively and critically discussed. The distinct and overlapping features of ALS and FTD are pointed out, as well as the undisclosed questions deserving additional studies.

Entities:  

Mesh:

Year:  2010        PMID: 20953810     DOI: 10.1007/s10072-010-0439-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  79 in total

Review 1.  The cognitive profile of amyotrophic lateral sclerosis: A meta-analysis.

Authors:  Joost Raaphorst; Marianne de Visser; Wim H J P Linssen; Rob J de Haan; Ben Schmand
Journal:  Amyotroph Lateral Scler       Date:  2010

2.  The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study.

Authors:  J J Kew; L H Goldstein; P N Leigh; S Abrahams; N Cosgrave; R E Passingham; R S Frackowiak; D J Brooks
Journal:  Brain       Date:  1993-12       Impact factor: 13.501

3.  Antemortem diagnosis of frontotemporal lobar degeneration.

Authors:  David S Knopman; Bradley F Boeve; Joseph E Parisi; Dennis W Dickson; Glenn E Smith; Robert J Ivnik; Keith A Josephs; Ronald C Petersen
Journal:  Ann Neurol       Date:  2005-04       Impact factor: 10.422

4.  The overlap of amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Catherine Lomen-Hoerth; Thomas Anderson; Bruce Miller
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

5.  Cognitive change in ALS: a prospective study.

Authors:  S Abrahams; P N Leigh; L H Goldstein
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

6.  Broad clinical phenotypes associated with TAR-DNA binding protein (TARDBP) mutations in amyotrophic lateral sclerosis.

Authors:  Janine Kirby; Emily F Goodall; William Smith; J Robin Highley; Rudo Masanzu; Judith A Hartley; Rachel Hibberd; Hannah C Hollinger; Stephen B Wharton; Karen E Morrison; Paul G Ince; Christopher J McDermott; Pamela J Shaw
Journal:  Neurogenetics       Date:  2009-09-17       Impact factor: 2.660

7.  Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease.

Authors:  Nicholas J Brandmeir; Felix Geser; Linda K Kwong; Earl Zimmerman; Jiang Qian; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2007-11-15       Impact factor: 17.088

Review 8.  The neuropathology of FTD associated With ALS.

Authors:  Ian R A Mackenzie
Journal:  Alzheimer Dis Assoc Disord       Date:  2007 Oct-Dec       Impact factor: 2.703

9.  Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.

Authors:  Ian R A Mackenzie; Eileen H Bigio; Paul G Ince; Felix Geser; Manuela Neumann; Nigel J Cairns; Linda K Kwong; Mark S Forman; John Ravits; Heather Stewart; Andrew Eisen; Leo McClusky; Hans A Kretzschmar; Camelia M Monoranu; J Robin Highley; Janine Kirby; Teepu Siddique; Pamela J Shaw; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

10.  Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3.

Authors:  Caroline Vance; Ammar Al-Chalabi; Deborah Ruddy; Bradley N Smith; Xun Hu; Jemeen Sreedharan; Teepu Siddique; H Jurgen Schelhaas; Benno Kusters; Dirk Troost; Frank Baas; Vianney de Jong; Christopher E Shaw
Journal:  Brain       Date:  2006-02-22       Impact factor: 13.501

View more
  34 in total

1.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 2.  Patterns of Weakness, Classification of Motor Neuron Disease, and Clinical Diagnosis of Sporadic Amyotrophic Lateral Sclerosis.

Authors:  Jeffrey M Statland; Richard J Barohn; April L McVey; Jonathan S Katz; Mazen M Dimachkie
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

Review 3.  Association between essential tremor and other neurodegenerative diseases: what is the epidemiological evidence?

Authors:  Hiral LaRoia; Elan D Louis
Journal:  Neuroepidemiology       Date:  2011-07-13       Impact factor: 3.282

Review 4.  Mechanisms of toxicity in C9FTLD/ALS.

Authors:  Tania F Gendron; Veronique V Belzil; Yong-Jie Zhang; Leonard Petrucelli
Journal:  Acta Neuropathol       Date:  2014-01-07       Impact factor: 17.088

Review 5.  Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era.

Authors:  Ximena Paez-Colasante; Claudia Figueroa-Romero; Stacey A Sakowski; Stephen A Goutman; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2015-04-21       Impact factor: 42.937

Review 6.  How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?

Authors:  Marka van Blitterswijk; Mariely DeJesus-Hernandez; Rosa Rademakers
Journal:  Curr Opin Neurol       Date:  2012-12       Impact factor: 5.710

7.  Clinicopathologic report of ocular involvement in ALS patients with C9orf72 mutation.

Authors:  Amani A Fawzi; Joseph M Simonett; Patryk Purta; Heather E Moss; Jessica L Lowry; Han-Xiang Deng; Nailah Siddique; Robert Sufit; Eileen H Bigio; Nicholas J Volpe; Teepu Siddique
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-10-16       Impact factor: 4.092

Review 8.  Protein sequestration as a normal function of long noncoding RNAs and a pathogenic mechanism of RNAs containing nucleotide repeat expansions.

Authors:  Ginny R Morriss; Thomas A Cooper
Journal:  Hum Genet       Date:  2017-05-08       Impact factor: 4.132

9.  A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration.

Authors:  Masataka Nakamura; Kevin F Bieniek; Wen-Lang Lin; Neill R Graff-Radford; Melissa E Murray; Monica Castanedes-Casey; Pamela Desaro; Matthew C Baker; Nicola J Rutherford; Janice Robertson; Rosa Rademakers; Dennis W Dickson; Kevin B Boylan
Journal:  Acta Neuropathol       Date:  2015-04-28       Impact factor: 17.088

10.  Telephone based cognitive-behavioral screening for frontotemporal changes in patients with amyotrophic lateral sclerosis (ALS).

Authors:  Georgia Christodoulou; Chris Gennings; Jonathan Hupf; Pam Factor-Litvak; Jennifer Murphy; Raymond R Goetz; Hiroshi Mitsumoto
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-04-28       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.